Floatz logo

Zometa

Prostate Cancer

Central European Cooperative Oncology GroupPhase 4 / ApprovedDormant
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
67/ 100
Competitive Position
59/ 100

Competitive context

514 Active assets in the Prostate Cancer cohort.

Asset / SponsorPhaseRating
Avodart
Bay State Clinical Trials, Inc.
Phase 4BBB
Desflurane
Peter MacCallum Cancer Centre, Australia
Phase 4BBB
Degarelix
Bayer
Phase 4BBB
PROPOFOL
Peter MacCallum Cancer Centre, Australia
Phase 4BBB
Fluciclovine
NRG Oncology
Phase 4BB

View all 50 →

Same molecule, other indications

Zometa is also rated in:

metastatic carcinoma in the boneDormant
BB
Indicative ·
68 / 100
View asset →
plasma cell myelomaDormant
B
Indicative ·
60 / 100
View asset →
non-small cell lung carcinomaDormant
B
Indicative ·
58 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →